MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ejhf.2982

Медицинская библиотека · European journal of heart failure · 2023

Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.

Ferreira João Pedro, Blatchford Jonathan P, Teerlink John R, Kosiborod Mikhail N, Angermann Christiane E, Biegus Jan, Collins Sean P, Tromp Jasper, Nassif Michael E, Psotka Mitchell A, Comin-Colet Josep, Mentz Robert J, Brueckmann Martina, Nordaby Matias, Ponikowski Piotr, Voors Adriaan A

Рандомизированное исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIMS: In patients hospitalized for acute heart failure (AHF) empagliflozin produced greater clinical benefit than placebo. Many patients with AHF are treated with mineralocorticoid receptor antagonists (MRAs). The interplay between empagliflozin and MRAs in AHF is yet to be explored. This study aimed to evaluate the efficacy and safety of empagliflozin versus placebo according to MRA use at baseline in the EMPULSE trial (NCT04157751).

METHODS AND

RESULTS

In this analysis all comparisons were performed between empagliflozin and placebo, stratified by baseline MRA use. The primary outcome included all-cause death, heart failure events, and a ≥5 point difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score at 90 days, assessed using the win ratio (WR). First heart failure hospitalization or cardiovascular death was a secondary outcome. From the 530 patients randomized, 276 (52%) were receiving MRAs at baseline. MRA users were younger, had lower ejection fraction, better renal function, and higher KCCQ scores. The primary outcome showed benefit of empagliflozin irrespective of baseline MRA use (WR 1.46, 95% confidence interval [CI] 1.08-1.97 and WR 1.27, 95% CI 0.93-1.73 in MRA users and non-users, respectively; interaction p = 0.52). The effect of empagliflozin on first heart failure hospitalization or cardiovascular death was not modified by MRA use (hazard ratio [HR] 0.58, 95% CI 0.30-1.11 and HR 0.85, 95% CI 0.47-1.52 in MRA users and non-users, respectively; interaction p = 0.39). Investigator-reported and severe hyperkalaemia events were infrequent (<6%) irrespective of MRA use.

CONCLUSIONS

In patients admitted for AHF, initiation of empagliflozin produced clinical benefit and was well tolerated irrespective of background MRA use. These findings support the early use of empagliflozin on top of MRA therapy in patients admitted for AHF.

Для цитирования: Ferreira João Pedro, Blatchford Jonathan P, Teerlink John R, Kosiborod Mikhail N, Angermann Christiane E, Biegus Jan, Collins Sean P, Tromp Jasper, Nassif Michael E, Psotka Mitchell A, Comin-Colet Josep, Mentz Robert J, Brueckmann Martina, Nordaby Matias, Ponikowski Piotr, Voors Adriaan A. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.. European journal of heart failure. 2023. DOI: 10.1002/ejhf.2982.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.